These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 24875081)

  • 21. OSI-461 (OSI).
    Galmarini CM
    Curr Opin Investig Drugs; 2004 Jun; 5(6):648-56. PubMed ID: 15242254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epothilone D (Kosan/Roche).
    Kolman A
    Curr Opin Investig Drugs; 2004 Jun; 5(6):657-67. PubMed ID: 15242255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Marking off new territory in the search for anticancer compounds: epigenetic mechanisms add complexity and promise to cancer research efforts.
    Nelson B
    Cancer Cytopathol; 2012 Jun; 120(3):143-4. PubMed ID: 22692980
    [No Abstract]   [Full Text] [Related]  

  • 24. CYC-202 Cyclacel.
    Guzi T
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1311-8. PubMed ID: 15648953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Researchers may use cancer cell lines to identify target populations prior to clinical trials.
    Tuma RS
    J Natl Cancer Inst; 2006 Jun; 98(12):810-1. PubMed ID: 16788154
    [No Abstract]   [Full Text] [Related]  

  • 26. New NCI drug formulary cuts red tape.
    Weintraub A
    Lab Anim (NY); 2017 Jun; 46(7):285. PubMed ID: 28644447
    [No Abstract]   [Full Text] [Related]  

  • 27. MS-209 Schering.
    Robert J
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1340-7. PubMed ID: 15648956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 27th Annual JPMorgan Healthcare Conference--Antisoma and Keryx Biopharmaceuticals.
    Croasdell G; Gale S
    IDrugs; 2009 Mar; 12(3):152-4. PubMed ID: 19333892
    [No Abstract]   [Full Text] [Related]  

  • 29. Setback prompts rethink of latency-reversing strategy to eliminate HIV infection.
    Katsnelson A
    Nat Rev Drug Discov; 2014 Jun; 13(6):403-4. PubMed ID: 24875082
    [No Abstract]   [Full Text] [Related]  

  • 30. Lapatinib ditosylate GlaxoSmithKline.
    Kim TE; Murren JR
    IDrugs; 2003 Sep; 6(9):886-93. PubMed ID: 12964069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. American Society of Clinical Oncology Developing First Clinical Trial.
    Brower V
    J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug discovery conference 2008. Small-Molecule Drug Discovery: From Early Stage to the Clinic.
    Terrett NK
    IDrugs; 2008 Mar; 11(3):164-8. PubMed ID: 18311648
    [No Abstract]   [Full Text] [Related]  

  • 33. The era of cancer discovery.
    Cantley LC; Baselga J
    Cancer Discov; 2011 Jun; 1(1):1. PubMed ID: 22586302
    [No Abstract]   [Full Text] [Related]  

  • 34. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.
    Christian MC; Pluda JM; Ho PT; Arbuck SG; Murgo AJ; Sausville EA
    Semin Oncol; 1997 Apr; 24(2):219-40. PubMed ID: 9129691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One community. The B. Chevalier Lecture, held at the EORTC New Drugs Meeting, Lugano, Switzerland, 19-21 June 1997.
    Wittes RE; Yoder O
    Ann Oncol; 1998 Mar; 9(3):251-4. PubMed ID: 9602257
    [No Abstract]   [Full Text] [Related]  

  • 36. Institutional profile: Developing and evaluating new drugs for cancer treatment: perspectives from the US National Cancer Institute.
    Trimble EL; Abrams JS; Ansher SS; Smith MA; Zwiebel JA; Tomaszewski JE
    Future Med Chem; 2010 Apr; 2(4):555-9. PubMed ID: 21426005
    [No Abstract]   [Full Text] [Related]  

  • 37. Expanded Access Allows for Compassionate Use of Investigational Cancer Drugs.
    Miller D
    ONS Connect; 2015 Jun; 30(2):47. PubMed ID: 26137830
    [No Abstract]   [Full Text] [Related]  

  • 38. Cooperation needed to optimise cancer drug development.
    Mayor S
    Lancet; 2004 Mar; 363(9414):1045. PubMed ID: 15065559
    [No Abstract]   [Full Text] [Related]  

  • 39. The National Cancer Institute: cancer drug discovery and development program.
    Grever MR; Schepartz SA; Chabner BA
    Semin Oncol; 1992 Dec; 19(6):622-38. PubMed ID: 1462164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncology's first Phase 0 trial.
    Rowan K
    J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.